Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration

Hormones

Volumn 11, Issue 4, 2012, Pages 444-450

  Alexiadou, Kleopatra ^a   Kokkinos, Alexander ^a   Liatis, Stavros ^a   Perrea, Despoina ^a   Katsilambros, Nicholas ^a   Tentolouris, Nicholas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adipokines; Insulin secretion; Oral glucose tolerance test

Indexed keywords

APELIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN LISPRO; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL;

EID: 84871994542     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1376     Document Type: Article

References (41)

1. Lee DK, Cheng R, Nguyen T, et al, 2000 Characterization of apelin, the ligand for the APJ receptor. J Neurochem 74: 34-41.
2. T atemoto K, Takayama K, Zou MX, et al, 2001 The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 99: 87-92.
3. Kleinz MJ, Davenport AP, 2005 Emerging roles of apelin in biology and medicine. Pharmacol Ther 107: 198-211.
4. Boucher J, Masri B, Daviaud D, et al, 2005 Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146: 1764-1771.
5. Bełtowski J, 2006 Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit 12: RA112-119.
6. Szokodi I, Tavi P, Földes G, et al, 2002 Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91: 434-440.
7. A shley EA, Powers J, Chen M, et al, 2005 The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 65: 73-82.
8. Sunter D, Hewson AK, Dickson SL, 2003 Intracerebroventricular injection of apelin-13 reduces food intake in the rat. Neurosci Lett 353: 1-4.
9. O 'Shea M, Hansen MJ, Tatemoto K, Morris MJ, 2003 Inhibitory effect of apelin-12 on nocturnal food intake in the rat. Nutr Neurosci 6: 163-167.
10. Jászberényi M, Bujdosó E, Telegdy G, 2004 Behavioral, neuroendocrine and thermoregulatory actions of apelin-13. Neuroscience 129: 811-816.
11. T aheri S, Murphy K, Cohen M, et al, 2002 The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 291: 1208-1212.
12. Reaux A, De Mota N, Skultetyova I, et al, 2001 Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem 77: 1085-1096.
13. Reaux-Le Goazigo A, Morinville A, Burlet A, Llorens-Cortes C, Beaudet A, 2004 Dehydration-induced crossregulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons. Endocrinology 145: 4392-4400.
14. Kasai A, Shintani N, Oda M, et al, 2004 Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 325: 395-400.
15. X ie H, Yuan LQ, Luo XH, et al, 2007 Apelin suppresses apoptosis of human osteoblasts. Apoptosis 12: 247-254.
16. Daviaud D, Boucher J, Gesta S, et al, 2006 TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J 20: 1528-1530.
17. Brown JE, Onyango DJ, Ramanjaneya M, et al, 2010 Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. J Mol Endocrinol 44: 171-178.
18. Meral C, Tascilar E, Karademir F, et al, 2010 Elevated plasma levels of apelin in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 23: 497-502.
19. T elejko B, Kuzmicki M, Wawrusiewicz-Kurylonek N, et al, 2010 Plasma apelin levels and apelin/APJ mRNA expression in patients with gestational diabetes mellitus. Diabetes Res Clin Pract 87: 176-183.
20. Matthews JN, Altman DG, Campbell MJ, Royston P, 1990 Analysis of serial measurements in medical research. BMJ 300: 230-235.
21. Li L, Yang G, Li Q, et al, 2006 Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 114: 544-548.
22. Heinonen MV, Purhonen AK, Miettinen P, et al, 2005 Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 130: 7-13.
23. Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, et al, 2009 Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg 19: 1574-1580.
24. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S, 2008 Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116: 289-292.
25. Z hang Y, Shen C, Li X, et al, 2009 Low plasma apelin in newly diagnosed type 2 diabetes in Chinese people. Diabetes Care 32: e150.
26. Higuchi K, Masaki T, Gotoh K, et al, 2007 Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology 148: 2690-2697.
27. Dray C, Knauf C, Daviaud D, et al, 2008 Apelin stimulates glucose utilization in normal and obese insulin--resistant mice. Cell Metab 8: 437-445.
28. Yue P, Jin H, Aillaud M, et al, 2010 Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab 298: E59-67.
29. Castan-Laurell I, Vítkova M, Daviaud D, et al, 2008 Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol 158: 905-910.
30. Sörhede Winzell M, Magnusson C, Ahrén B, 2005 The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept 131: 12-17.
31. Chen MP, Chung FM, Chang DM, et al, 2006 Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91: 295-299.
32. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B, 2006 Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91: 1578-1581.
33. Filippatos TD, Derdemezis CS, Gazi IF, et al, 2008 Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 38: 71-72.
34. Berndt J, Klöting N, Kralisch S, et al, 2005 Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54: 2911-2916.
35. Pagano C, Pilon C, Olivieri M, et al, 2006 Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91: 3165-3170.
36. O ki K, Yamane K, Kamei N, Nojima H, Kohno N, 2007 Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 67: 796-800.
37. Dogru T, Sonmez A, Tasci I, et al, 2007 Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 76: 24-29.
38. T oruner F, Altinova AE, Bukan N, et al, 2009 Plasma visfatin concentrations in subjects with type 1 diabetes mellitus. Horm Res 72: 33-37.
39. López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, et al, 2006 Serum visfatin increases with progressive beta-cell deterioration. Diabetes 55: 2871-2875.
40. Revollo JR, Körner A, Mills KF, et al, 2007 Nampt/ PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363-375.
41. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M, 2006 The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49: 1909.